Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

doi:10.1016/j.ucl.2020.04.002

Review

. 2020 Aug;47(3):293-303.

doi: 10.1016/j.ucl.2020.04.002. Epub 2020 Jun 10.

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Kyrollis Attalla¹, Stanley Weng¹, Martin H Voss¹, A Ari Hakimi²

Affiliations

¹ Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, 5th Floor, New York, NY 10065, USA.
² Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, 5th Floor, New York, NY 10065, USA. Electronic address: hakimia@mskcc.org.

PMID: 32600532
PMCID: PMC8327324
DOI: 10.1016/j.ucl.2020.04.002

Review

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Kyrollis Attalla et al. Urol Clin North Am. 2020 Aug.

. 2020 Aug;47(3):293-303.

doi: 10.1016/j.ucl.2020.04.002. Epub 2020 Jun 10.

Authors

Kyrollis Attalla¹, Stanley Weng¹, Martin H Voss¹, A Ari Hakimi²

Affiliations

¹ Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, 5th Floor, New York, NY 10065, USA.
² Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, 5th Floor, New York, NY 10065, USA. Electronic address: hakimia@mskcc.org.

PMID: 32600532
PMCID: PMC8327324
DOI: 10.1016/j.ucl.2020.04.002

Abstract

In the preceding two decades, several milestones have been reached in the management of patients with metastatic renal cell carcinoma (mRCC), including the development of novel targeted agents paralleling an increased understanding of the molecular biology of this disease process. Recently, a renewed enthusiasm for immunotherapy in the form of immune checkpoint blockade has resulted in significant strides in the treatment of mRCC. Despite these advances, treatment remains challenging for clinicians, and only modest survival benefits are observed with current treatment paradigms. The risk-stratification tools and investigated predictive and prognostic biomarkers in patients with mRCC are detailed in this review.

Keywords: Immunotherapy; Metastatic renal cell carcinoma; Predictive biomarker; Prognostic biomarker; Risk assessment; Targeted therapy.

PubMed Disclaimer

Figures

**Fig. 1.**
Biomarkers in RCC. BMI, body mass index; CT, computed tomography.

See this image and copyright information in PMC

Cited by

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.
Rebuzzi SE, Signori A, Stellato M, Santini D, Maruzzo M, De Giorgi U, Pedrazzoli P, Galli L, Zucali PA, Fantinel E, Carella C, Procopio G, Milella M, Boccardo F, Fratino L, Sabbatini R, Ricotta R, Panni S, Massari F, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Llaja Obispo MA, Porta C, Buti S, Fornarini G, Banna GL. Rebuzzi SE, et al. Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022. Front Oncol. 2022. PMID: 36212433 Free PMC article.
Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade Differentiation.
Hadisurya M, Lee ZC, Luo Z, Zhang G, Ding Y, Zhang H, Iliuk AB, Pili R, Boris RS, Tao WA. Hadisurya M, et al. Mol Cell Proteomics. 2023 May;22(5):100536. doi: 10.1016/j.mcpro.2023.100536. Epub 2023 Mar 29. Mol Cell Proteomics. 2023. PMID: 36997065 Free PMC article.
Trends in Stage-Specific Kidney Cancer Incidence in Kazakhstan, 2005-2019.
Igissin N, Dyakov S, Telmanova Z, Kudaibergenova I, Ayaganov S, Turebayev D, Jexenova A, Igissinova GS, Maukayeva S, Lust V, Grigorevsky V, Shelestyuk A, Syzdykov N, Shishkin I, Bilyalova Z. Igissin N, et al. Asian Pac J Cancer Prev. 2024 Sep 1;25(9):3239-3249. doi: 10.31557/APJCP.2024.25.9.3239. Asian Pac J Cancer Prev. 2024. PMID: 39342603 Free PMC article.
The Overexpression of NUSAP1 and GTSE1 Could Predict An Unfavourable Prognosis and Shorter Disease Free Survival in ccRenal Cell Carcinoma.
El-Hussieny M, Thabet DM, Tawfik HM, Gayyed MF, Toni ND. El-Hussieny M, et al. Asian Pac J Cancer Prev. 2024 Jul 1;25(7):2551-2559. doi: 10.31557/APJCP.2024.25.7.2551. Asian Pac J Cancer Prev. 2024. PMID: 39068590 Free PMC article.
Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens.
Tan Z, Völler S, Yin A, Rieborn A, Gelderblom AJ, van der Hulle T, Knibbe CAJ, Moes DJAR. Tan Z, et al. Clin Pharmacokinet. 2024 Jun;63(6):857-869. doi: 10.1007/s40262-024-01379-y. Epub 2024 Jun 14. Clin Pharmacokinet. 2024. PMID: 38874883 Free PMC article.

See all "Cited by" articles

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. - PubMed
1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477–90. - PubMed
1. Motzer RJ, Russo P, Nanus DM, et al. Renal cell carcinoma. Curr Probl Cancer 1997;21(4):185–232. - PubMed
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. - PubMed
1. Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma. Clin Dev Immunol 2010;2010:284581. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. - PubMed

[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. - PubMed

[3] Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477–90. - PubMed

[4] Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477–90. - PubMed

[5] Motzer RJ, Russo P, Nanus DM, et al. Renal cell carcinoma. Curr Probl Cancer 1997;21(4):185–232. - PubMed

[6] Motzer RJ, Russo P, Nanus DM, et al. Renal cell carcinoma. Curr Probl Cancer 1997;21(4):185–232. - PubMed

[7] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. - PubMed

[8] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30. - PubMed

[9] Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma. Clin Dev Immunol 2010;2010:284581. - PMC - PubMed

[10] Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma. Clin Dev Immunol 2010;2010:284581. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Affiliations

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical